Phaseline

Companies › Huahui Health

Huahui Health: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Infectious disease; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Libevitug
Unclear - specific mechanism not stated in registry
–Phase 3Chronic Hepatitis D InfectionSep 2028
HH-006–Phase 2Chronic Hepatitis B Virus InfectionFeb 2028
HH160–Phase 1Solid TumorAug 2027
HH-009
FGF19 antagonist
FGF19Phase 1Advanced or Unresectable Hepatocellular Carcinoma (HCC)Oct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07623369HH160Phase 1Solid TumorOncologyAug 2027
NCT07519330HH-006Phase 2Chronic Hepatitis B Virus InfectionInfectious diseaseFeb 2028
NCT07499544LibevitugPhase 3Chronic Hepatitis D InfectionInfectious diseaseSep 2028
NCT07547553HH-009Phase 1Advanced or Unresectable Hepatocellular Carcinoma (HCC)OncologyOct 2028

Targets

FGF19 (1)

Companies with the same targets

Abbisko Therapeutics

Companies built like this

Newish Biotech (Wuxi) Cantex Pharmaceuticals Lantheus Medical Imaging Jiangsu Aosaikang Pharmaceutical Henan Genuine Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.